Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company using biomarkers and augmented intelligence to help physicians identify the source of chronic low back pain, released a shareholder letter from CEO Brent Ness on March 19, 2026. The letter highlights the company's strategic progress and value-creating priorities for the year.
Key catalysts outlined include pursuing reimbursement coverage from one or more regional insurance providers in the United States, which the company views as an important step toward broader payer adoption. Additionally, Aclarion expects an initial readout from its ongoing CLARITY clinical trial in the fourth quarter of 2026. The company also emphasized its strong balance sheet, with a cash runway that extends into 2028, providing financial stability for continued execution.
“Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Ness. “With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.”
Aclarion's Nociscan platform uses magnetic resonance spectroscopy data from MRI machines to quantify chemical biomarkers associated with disc pain. Proprietary algorithms then indicate whether a disc may be a source of pain, providing critical insights for treatment strategies. The company is also advancing reimbursement initiatives in the United Kingdom alongside its U.S. efforts.
The full CEO shareholder letter is available on the company's website. For more news from Aclarion, visit their newsroom.
